BioCentury | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

...The compound could find uses in other indications. An ongoing investigator-led trial run from the University Medical Center Hamburg-Eppendorf...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...3895 Protein S (PROS1) MM Mouse; cell-based Overexpression of PROS1 promotes destructive myeloma bone disease. University Medical Center Hamburg-Eppendorf...
BioCentury | Sep 1, 2017
Company News

Lilly backs Topas' liver-specific nanoparticles platform

...difficulty escaping the liver -- into an advantage. The discovery underlying the technology originated at University Medical Center Hamburg-Eppendorf...
BioCentury | Aug 22, 2017
Company News

Lilly backs Topas' liver-specific nanoparticles platform

...difficulty escaping the liver -- into an advantage. The discovery underlying the technology originated at University Medical Center Hamburg-Eppendorf...
BioCentury | Jan 3, 2017
Distillery Therapeutics

Inflammation; dermatology; renal

...published online Nov. 23, 2016 doi:10.1126/scitranslmed.aaf8463 CONTACT: Friedrich Koch-Nolte, University Medical Center Hamburg-Eppendorf, Hamburg, Germany email: nolte@uke.de Hongjiang Li University Medical Center Hamburg-Eppendorf Interleukin-1...
BioCentury | Nov 3, 2016
Translation in Brief

The I’s have it

...pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease.” Science (2016) - Michael Leviten Michael Leviten University Medical Center Hamburg-Eppendorf Interleukin-22...
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: E. coli exopolyphosphatase (PPX)

...Labberton, L. et al. Nat. Comm.; published online Sept. 6, 2016 doi:10.1038/ncomms12616 CONTACT: Thomas Renné, University Medical Center Hamburg-Eppendorf...
BioCentury | May 9, 2016
Emerging Company Profile

Deliver to the liver

...of the peptides," said CEO Timm Jessen. The discovery underlying the company's technology originated at University Medical Center Hamburg-Eppendorf...
...Applied Nanotechnology GmbH, Hamburg, Germany Evotec AG (Xetra:EVT), Hamburg, Germany Topas Therapeutics GmbH, Hamburg, Germany University Medical Center Hamburg-Eppendorf...
...Clinical status: Preclinical Founded: 2016 by Timm Jessen, John Pohlner and Evotec AG University collaborators: University Medical Center Hamburg-Eppendorf...
BioCentury | Mar 28, 2016
Finance

Back in the game

...I testing of its unnamed lead product to treat multiple sclerosis. The product originated at University Medical Center Hamburg-Eppendorf...
BioCentury | Mar 23, 2016
Financial News

Topas spins out of Evotec, raises series A

...universities when it acquired Bionamics GmbH in 2014. Topas' platform was exclusively licensed from the University Medical Center Hamburg-Eppendorf...
Items per page:
1 - 10 of 25
BioCentury | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

...The compound could find uses in other indications. An ongoing investigator-led trial run from the University Medical Center Hamburg-Eppendorf...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...3895 Protein S (PROS1) MM Mouse; cell-based Overexpression of PROS1 promotes destructive myeloma bone disease. University Medical Center Hamburg-Eppendorf...
BioCentury | Sep 1, 2017
Company News

Lilly backs Topas' liver-specific nanoparticles platform

...difficulty escaping the liver -- into an advantage. The discovery underlying the technology originated at University Medical Center Hamburg-Eppendorf...
BioCentury | Aug 22, 2017
Company News

Lilly backs Topas' liver-specific nanoparticles platform

...difficulty escaping the liver -- into an advantage. The discovery underlying the technology originated at University Medical Center Hamburg-Eppendorf...
BioCentury | Jan 3, 2017
Distillery Therapeutics

Inflammation; dermatology; renal

...published online Nov. 23, 2016 doi:10.1126/scitranslmed.aaf8463 CONTACT: Friedrich Koch-Nolte, University Medical Center Hamburg-Eppendorf, Hamburg, Germany email: nolte@uke.de Hongjiang Li University Medical Center Hamburg-Eppendorf Interleukin-1...
BioCentury | Nov 3, 2016
Translation in Brief

The I’s have it

...pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease.” Science (2016) - Michael Leviten Michael Leviten University Medical Center Hamburg-Eppendorf Interleukin-22...
BioCentury | Oct 13, 2016
Distillery Therapeutics

Therapeutics: E. coli exopolyphosphatase (PPX)

...Labberton, L. et al. Nat. Comm.; published online Sept. 6, 2016 doi:10.1038/ncomms12616 CONTACT: Thomas Renné, University Medical Center Hamburg-Eppendorf...
BioCentury | May 9, 2016
Emerging Company Profile

Deliver to the liver

...of the peptides," said CEO Timm Jessen. The discovery underlying the company's technology originated at University Medical Center Hamburg-Eppendorf...
...Applied Nanotechnology GmbH, Hamburg, Germany Evotec AG (Xetra:EVT), Hamburg, Germany Topas Therapeutics GmbH, Hamburg, Germany University Medical Center Hamburg-Eppendorf...
...Clinical status: Preclinical Founded: 2016 by Timm Jessen, John Pohlner and Evotec AG University collaborators: University Medical Center Hamburg-Eppendorf...
BioCentury | Mar 28, 2016
Finance

Back in the game

...I testing of its unnamed lead product to treat multiple sclerosis. The product originated at University Medical Center Hamburg-Eppendorf...
BioCentury | Mar 23, 2016
Financial News

Topas spins out of Evotec, raises series A

...universities when it acquired Bionamics GmbH in 2014. Topas' platform was exclusively licensed from the University Medical Center Hamburg-Eppendorf...
Items per page:
1 - 10 of 25